Home > Publications database > Unveiling IRF4-steered regulation of context-dependent effector programs in CD4+ T cells under Th17- and Treg-skewing conditions. > print

001     299791
005     20250316015809.0
024 7 _ |a 10.1016/j.celrep.2025.115407
|2 doi
024 7 _ |a pmid:40067830
|2 pmid
024 7 _ |a 2211-1247
|2 ISSN
024 7 _ |a 2639-1856
|2 ISSN
024 7 _ |a altmetric:175063454
|2 altmetric
037 _ _ |a DKFZ-2025-00546
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Gabele, Anna
|b 0
245 _ _ |a Unveiling IRF4-steered regulation of context-dependent effector programs in CD4+ T cells under Th17- and Treg-skewing conditions.
260 _ _ |a Maryland Heights, MO
|c 2025
|b Cell Press
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1741876150_9597
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a HI-TRON
520 _ _ |a The transcription factor interferon regulatory factor 4 (IRF4) is crucial for the fate determination of pro-inflammatory T helper (Th) 17 and the functionally opposing group of immunomodulatory regulatory T (Treg) cells. However, the molecular mechanisms of how IRF4 steers diverse transcriptional programs in Th17 and Treg cells are far from being definitive. Here, we integrated data derived from affinity-purification and full mass-spectrometry-based proteome analysis with chromatin immunoprecipitation sequencing. This allowed the characterization of subtype-specific molecular programs and the identification of IRF4 interactors in the Th17/Treg context. Our data reveal that IRF4-interacting transcription factors are recruited to IRF composite elements for the regulation of cell-type-specific transcriptional programs as exemplarily demonstrated for FLI1, which, in cooperation with IRF4, promotes Th17-specific gene expression. FLI1 inhibition markedly impaired Th17 differentiation. The present 'omics' dataset provides a valuable resource for studying IRF4-mediated gene regulatory programs in pro- and anti-inflammatory immune responses.
536 _ _ |a 314 - Immunologie und Krebs (POF4-314)
|0 G:(DE-HGF)POF4-314
|c POF4-314
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a CP: Immunology
|2 Other
650 _ 7 |a ChIP-seq
|2 Other
650 _ 7 |a FLI1
|2 Other
650 _ 7 |a IRF4
|2 Other
650 _ 7 |a Th17 cells
|2 Other
650 _ 7 |a Treg cells
|2 Other
650 _ 7 |a composite motif
|2 Other
650 _ 7 |a protein-protein interaction
|2 Other
650 _ 7 |a proteomics
|2 Other
700 1 _ |a Sprang, Maximilian
|b 1
700 1 _ |a Cihan, Mert
|b 2
700 1 _ |a Welzel, Mareen
|b 3
700 1 _ |a Nurbekova, Assel
|b 4
700 1 _ |a Romaniuk, Karolina
|b 5
700 1 _ |a Dietzen, Sarah
|b 6
700 1 _ |a Klein, Matthias
|b 7
700 1 _ |a Bündgen, Georg
|b 8
700 1 _ |a Emelianov, Maxim
|b 9
700 1 _ |a Harms, Gregory
|b 10
700 1 _ |a Rajalingam, Krishnaraj
|b 11
700 1 _ |a Ziesmann, Tanja
|b 12
700 1 _ |a Pape, Katrin
|b 13
700 1 _ |a Wasser, Beatrice
|b 14
700 1 _ |a Gomez-Zepeda, David
|0 P:(DE-He78)4569ef2919d2438765ad71515f53646b
|b 15
|u dkfz
700 1 _ |a Braband, Kathrin
|b 16
700 1 _ |a Delacher, Michael
|b 17
700 1 _ |a Lemmermann, Niels
|b 18
700 1 _ |a Bittner, Stefan
|b 19
700 1 _ |a Andrade-Navarro, Miguel A
|b 20
700 1 _ |a Tenzer, Stefan
|0 P:(DE-He78)74e391c68d7926be83d679f3d8891e33
|b 21
|u dkfz
700 1 _ |a Luck, Katja
|b 22
700 1 _ |a Bopp, Tobias
|b 23
700 1 _ |a Distler, Ute
|b 24
773 _ _ |a 10.1016/j.celrep.2025.115407
|g Vol. 44, no. 3, p. 115407 -
|0 PERI:(DE-600)2649101-1
|n 3
|p 115407
|t Cell reports
|v 44
|y 2025
|x 2211-1247
909 C O |o oai:inrepo02.dkfz.de:299791
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 15
|6 P:(DE-He78)4569ef2919d2438765ad71515f53646b
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 21
|6 P:(DE-He78)74e391c68d7926be83d679f3d8891e33
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-314
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Immunologie und Krebs
|x 0
914 1 _ |y 2025
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-16
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CELL REP : 2022
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2023-05-02T08:49:39Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2023-05-02T08:49:39Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2023-05-02T08:49:39Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-16
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-16
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b CELL REP : 2022
|d 2024-12-16
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2024-12-16
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2024-12-16
920 1 _ |0 I:(DE-He78)D190-20160331
|k D190
|l HI-TRON zentral
|x 0
920 1 _ |0 I:(DE-He78)D191-20160331
|k D191
|l Hi-TRON Immunoproteomik
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)D190-20160331
980 _ _ |a I:(DE-He78)D191-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21